Literature DB >> 8135629

Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.

T Ruitenbeek1, A S Gouw, S Poppema.   

Abstract

This study was designed to assess whether monoclonal antibody MOC-31, which recognizes a membrane glycoprotein of 40-kd molecular weight present on epithelial cells and not on mesothelial cells, is a useful adjunct in the differential diagnosis of reactive pleural or ascitic fluids and adenocarcinoma. A panel of antibodies against carcinoembryonic antigen, epithelial membrane antigen, vimentin (antivimentin), keratin 18 (RGE-53), and cytokeratins of several molecular weights (AE1/AE3) was employed for comparison. Ninety-eight cases were selected based on the availability of pleural and peritoneal biopsy specimens for histologic confirmation. All cases with adenocarcinoma stained MOC-31 positive, including three cases that had not been identified by morphologic criteria. All cases of reactive mesothelial hyperplasia were negative, as well as five cases of malignant mesothelioma. One case of squamous cell carcinoma was also negative. Anti-carcinoembryonic antigen only identified half of the carcinoma cases, and anti-epithelial membrane antigen and both anticytokeratin antibodies were positive in the majority of tumor cells as well as in the mesothelial cells. This study indicates that monoclonal antibody MOC-31 is a highly sensitive and reliable reagent in the differential diagnosis between mesothelial and epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135629

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Isolation and characterization of a human hepatic epithelial-like cell line (AKN-1) from a normal liver.

Authors:  A K Nussler; G Vergani; S M Gollin; K Dorko; S M Morris; A J Demetris; M Nomoto; H G Beger; S C Strom
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-04       Impact factor: 2.416

2.  Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.

Authors:  P Athanassiadou; M Gonidi; A Liossi; E Petrakakou; L Nakopoulou; C Zerva; P Athanassiades
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Qianjing Hu; Yongchun Shen; Dan Xu; Tao Wang; Fuqiang Wen
Journal:  Tumour Biol       Date:  2014-03-08

Review 4.  Immunocytochemistry of effusions: Processing and commonly used immunomarkers.

Authors:  Vinod B Shidham; Beata Janikowski
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

5.  OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.

Authors:  C Edwards; J Oates
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

6.  Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.

Authors:  Robert Pilarski; Colleen M Cebulla; James B Massengill; Karan Rai; Thereasa Rich; Louise Strong; Barbara McGillivray; Mary-Jill Asrat; Frederick H Davidorf; Mohamed H Abdel-Rahman
Journal:  Genes Chromosomes Cancer       Date:  2013-11-15       Impact factor: 5.006

7.  Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.

Authors:  K Kahlos; P Pääkkö; E Kurttila; Y Soini; V L Kinnula
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

8.  Cytology Microarray on Cell Block Preparation: A Novel Diagnostic Approach in Fluid Cytology.

Authors:  Arghya Bandyopadhyay; Soumi Bhattacharyya; Shreosee Roy; Kaushik Majumdar; Kaushik Bose; Anup K Boler
Journal:  J Cytol       Date:  2019 Apr-Jun       Impact factor: 1.000

9.  Metastatic Seminoma with Positive Staining of Cytokeratin and MOC31: A Diagnostic Pitfall.

Authors:  Jiaming Fan; Ren Yuan; David Stefanelli; Gang Wang
Journal:  Case Rep Pathol       Date:  2021-06-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.